Advertisement

Clinical Pharmacokinetics

, Volume 46, Issue 9, pp 805–805 | Cite as

The Authors′ Reply

  • Matthias Schwab
Correspondence
  • 12 Downloads

Keywords

Inflammatory Bowel Disease Renal Transplantation Breast Milk Rheumatic Disease Therapeutic Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187–208PubMedCrossRefGoogle Scholar
  2. 2.
    Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504–17PubMedCrossRefGoogle Scholar
  3. 3.
    Mahadevan U, Kane S. American Gastroenterological Association Institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 278–82PubMedCrossRefGoogle Scholar
  4. 4.
    Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283–311PubMedCrossRefGoogle Scholar
  5. 5.
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 10. pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl. 4: 50–5Google Scholar
  6. 6.
    Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112–21PubMedCrossRefGoogle Scholar
  7. 7.
    Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006; 55: 1198–206PubMedCrossRefGoogle Scholar
  8. 8.
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia (PA): Lippincott, Williams & Wilkins, 2005Google Scholar
  9. 9.
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–13PubMedCrossRefGoogle Scholar
  10. 10.
    Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 Suppl. 1: S30–8PubMedGoogle Scholar
  11. 11.
    Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut 2003; 52: 140–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Matthias Schwab
    • 1
    • 2
  1. 1.Dr Margarete Fischer-Bosch Institute of Clinical PharmacologyStuttgart, and University of TübingenTübingenGermany
  2. 2.Department of Clinical PharmacologyUniversity HospitalTübingenGermany

Personalised recommendations